ONCBeOne Medicines Ltd.

$33B

Q2 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$595M+74.3% YoY

Gross Profit

$499M83.9% margin

Operating Income

-$319M-53.5% margin

Net Income

-$381M-64.0% margin

EPS (Diluted)

$-3.64

QoQ Revenue Growth

+32.9%

Cash Flow

Operating Cash Flow

-$294M

Free Cash Flow

-$415M

Stock-Based Comp.

$103M

Balance Sheet

Total Assets

$5.7B

Total Liabilities

$1.9B

Stockholders' Equity

$3.8B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$595M	$342M	+74.3%
Gross Profit	$499M	$270M	+84.6%
Operating Income	-$319M	-$439M	+27.5%
Net Income	-$381M	-$566M	+32.6%

ONC Q2 2023 Earnings — BeOne Medicines Ltd. Revenue & Financial Results | Market Cap Arena